Brenmiller Signs Memorandum of Understanding with India’s Largest SolarPanel Manufacturer

CEL-SCI Advances Regulatory Approval for Multikine

Mobilicom Expands Into New Geographic Markets

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Pluri’s PLX-R18

Test Driving LA’s Drive-Thru Haunted Houses

Single Rider Vehicles Could Be the Future of Urban Transportation

Oramed Protein Oral Delivery Technology (NASDAQ: ORMP) - French Language

Oramed Protein Oral Delivery Technology (NASDAQ: ORMP) - French Language

NYC Bars That Are All Fun and Games

What It's Like to Run Away With the Big Apple Circus

Competitive Eater vs. Most Expensive Sundae & Burger in NYC - $1.3K Challenge at Serendipity 3

The Race to Bring the First Oral Insulin Capsule to Market

The Rise of Smart Cities: Understanding the Future of Connected Living

Wize Pharma Hopes To Shake Up $3.7B RX Eye Drop Market

This NYC Bakery Can Turn Your Face Into a Cookie

Virtual Measurement App Aims to Disrupt Online Apparel Market

Virtual Tour of Louis Vuitton’s Volez, Voguez, Voyagez NYC Exhibition

Oramed Receives Approval to Conduct Clinical Study for Treatment of NASH w/ Oral Insulin

Behind the Scenes of the Macy’s Thanksgiving Day Parade 2017

PSTI Critical Limb Ischemia Phase III Trial Cleared in the US, UK, and Germany

Next Level NYC Movie Theaters | The NYC Urban Guidebook

US Open Ballperson: Making the Cut

CANF Commencing Patient Recruitment for Phase III Trial of Piclidenoson

Print Yourself in 3D | DOOB Custom Action Figures

Ladurée Pastry Class | Learn to Make the Best Selling Ispahan from Exec Chef Jimmy Leclerc

Backstage Pass to The Rolling Stones Exhibit w/ Curator Ileen Gallagher

Special Report : Cashless Society & Contactless Payments

Kitov Completes KIT-302 Testing for New Drug Application to FDA

The Past, Present and Future of Neon in New York w/ Let There Be Neon

PSTI Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency

Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH

NYC's Most Instagrammable Foods: The New Class

Discover the NYC Street Art Scene w/ Urban Art Expert Gabe Schoenberg – Graff Tours

PSTI Data Shows PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy

Kitov Reports KIT-302 Has Beneficial Effects on Kidney Function

TapImmune Begins Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

Oramed Announces $6.5 Million Milestone Payment from HTIT

Can-Fite Reports New Data on Psoriasis Drug Offering Efficacy Similar to Industry Leading Biologics

The Story of Jane’s Carousel – Interview w/ Jane Walentas

Eggloo’s Egg Waffle Ice Cream Cones Are NYC’s Newest Dessert Craze

Make New York Style Pizza at Home | Pizza a Casa Pizza School

The Most Dangerous Ride in NYC – PBR at MSG

The Changing Face of Transgender Surgery

Pluristem Signs MOU With Fukushima Medical University to Study PLX-R18 in Acute Radiation Syndrome

Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China

Can-Fite Announces Pre-Clinical Data on CF102 in the Treatment of NASH

Relive 40 Years of 'SNL' at 'Saturday Night Live': The Exhibition

Dario Diabetes Management Solution to Launch in India

Rexahn Reports Clinical Data for Archexin®

CEL-SCI’s Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan

U.S. FDA Grants Fast Track Designation to Can-Fite's CF102

Rexahn Pharmaceuticals Presents at the European Cancer Congress 2015

Oramed Patent Allowed in the US for Oral Administration of Proteins

Pluristem and NIAID Met With U.S. FDA and Agreed on Development Plan

Sneaker Culture Is on Display at the Brooklyn Museum

Corporate Profile of Anne-Marie Martinez - A.M.I. Lifestyle Creation Agency

New Data Show Pluristem's PLX Cells Regulate the Immune System

Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave

World Health Organization Accepted "Piclidenoson" as New Generic Name for Can-Fite's CF101

Sinopharm Capital-Hefei Signs Letter of Intent w/ ORMP for $50M Investment